Navigation Links
Regeneron Reports Third Quarter 2009 Financial and Operating Results
Date:11/3/2009

------- ------ ------- ------- Expenses Research and development 105,434 72,089 279,972 200,335 Selling, general, and administrative 12,840 11,103 35,892 35,652 Cost of goods sold 472 292 1,299 292 --- --- ----- --- 118,746 83,484 317,163 236,279 ------- ------ ------- ------- Loss from operations (1,291) (17,900) (34,695) (53,659) ------ ------- ------- ------- Other income (expense) Investment income 857 3,674 3,935 15,513 Interest expense (581) (1,772) (581) (7,457) Loss on early extinguishment of debt (7) (938) --- ----- ----- ----- 276 1,895 3,354 7,118 --- ----- ----- ----- Net loss before income tax expense (1,015) (16,005) (31,341) (46,541) Income tax expense 3,079 3,079 ----- ----- ------ ----- Net loss $(1,015) $(19,084) $(31,341) $(49,620) ======= ======== ======== ======== Net loss per share amounts, basic and diluted $(0.01) $(0.24) $(0.39) $(0.63) Weighted average shares outstanding, basic and diluted 79,866 78,937 79,663 78,706 * Revised as described in the paragraph of this press release titled "Revision of Previously Is
'/>"/>
SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Related medicine technology :

1. Bayer and Regeneron Dose First Patient in Second Phase 3 Study for VEGF Trap-Eye in Wet Age-Related Macular Degeneration
2. Bayer and Regeneron Extend Development Program for VEGF Trap-Eye to Include Central Retinal Vein Occlusion
3. Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
4. Regeneron Announces Presentation at the 18th Annual Credit Suisse Healthcare Conference
5. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
6. Spherix Reports Second Quarter Earnings
7. Tapestry Reports Second Quarter 2007 Results
8. Callisto Reports on Second-Quarter 2007 Milestones
9. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
10. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
11. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... -- The International Trade Commission (ITC) issued its final decision in ... a notice issued on December 23, the ITC ruled in ... humidifier was invalid. BMC President, James Xu ... excited with the ITC,s decision in this case. This victory ... the very beginning on the key patents in the case. ...
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, 2014 ... a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics ... medical need and commercial potential, today announced that ... 2,050,000 shares of its common stock and Series ... common stock.  Funds under the management of QVT ...
(Date:12/24/2014)... 23, 2014 Echo Therapeutics, Inc. (NASDAQ: ... focused on skin permeation, continuous glucose monitoring and ... Hollander has been appointed Chief Executive Officer ... than 20 years of experience in the medical ... recently served as Vice President, Business Development, Otsuka ...
Breaking Medicine Technology:ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 2Echo Therapeutics Announces Scott W. Hollander as President & Chief Executive Officer 3
... Matrixx Initiatives, Inc. (Nasdaq: MTXX ), an over-the-counter healthcare company, announced today ... March 31, 2010 , will be released after the market closes on ... following morning on Tuesday, May 11, 2010 at 11:00 AM ... To access the teleconference, ...
... that a new market research report is available in its catalogue: , ... Stakeholder Opinions: Cardiovascular and Metabolic Generics - Generics continue to gain prominence ... http://www.reportlinker.com/p0191948/Stakeholder-Opinions-Cardiovascular-and-Metabolic-Generics----Generics-continue-to-gain-prominence.html , ... , , , ...
Cached Medicine Technology:Matrixx Initiatives, Inc. Sets Time for Discussion of Fourth Quarter and Fiscal 2010 Financial Results 2Reportlinker Adds Stakeholder Opinions: Cardiovascular and Metabolic Generics - Generics continue to gain prominence 2Reportlinker Adds Stakeholder Opinions: Cardiovascular and Metabolic Generics - Generics continue to gain prominence 3Reportlinker Adds Stakeholder Opinions: Cardiovascular and Metabolic Generics - Generics continue to gain prominence 4Reportlinker Adds Stakeholder Opinions: Cardiovascular and Metabolic Generics - Generics continue to gain prominence 5Reportlinker Adds Stakeholder Opinions: Cardiovascular and Metabolic Generics - Generics continue to gain prominence 6Reportlinker Adds Stakeholder Opinions: Cardiovascular and Metabolic Generics - Generics continue to gain prominence 7Reportlinker Adds Stakeholder Opinions: Cardiovascular and Metabolic Generics - Generics continue to gain prominence 8Reportlinker Adds Stakeholder Opinions: Cardiovascular and Metabolic Generics - Generics continue to gain prominence 9
(Date:12/26/2014)... England (PRWEB) December 26, 2014 The ... take place March 24-28, 2015 in Rome, Italy and ... line-up includes workshops on a wide variety ... as well as peak performance training in athletes. The ... around the world. , Biofeedback monitoring allows clients to ...
(Date:12/26/2014)... Pentec Health, Inc. number fourteen on the ... for 2014. The awards program, created in 2000, is ... in the country. The program is a public/private partnership ... and Economic Development, the Pennsylvania State Council of the ... Business Journal. , Charlie Wilson, Vice President ...
(Date:12/25/2014)... December 26, 2014 This is a ... the global Sterilizers industry with a focus on the ... market status of the Sterilizers manufacturers and is a ... individuals interested in the industry. This report provides a ... and manufacturing technology. In this part, the report presents ...
(Date:12/25/2014)... December 25, 2014 Product liability lawsuits ... hip recall ( http://www.consumerinjurylawyers.com/DePuy/ ) continue to move forward ... an Order issued in the U.S. District Court, Northern ... convene an open conference on January 7, 2015, at ... Courthouse in West Palm Beach, Florida. The Conference is ...
(Date:12/25/2014)... December 25, 2014 The short film “Color ... created in honor of a true 9/11 hero, Welles Remy ... festivals including the 24 hours of Nuremberg International Short Film ... , Actress, screenwriter and director Luciana Lagana ... film together with her husband, Gregory Graham - ...
Breaking Medicine News(10 mins):Health News:Final Workshop Line-up Announced for 18th Annual Biofeedback Conference in Rome, Italy 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 2Health News:Pentec Health Ranks Fourteenth on The Best Places to Work in PA for 2014 3Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 2Health News:Sterilizers Industry Global and Chinese Analysis for 2009-2019 Now Available at ReportsnReports.com 3Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing DePuy ASR Hip Lawsuit Set to Convene Conference in January, Bernstein Liebhard LLP Reports 3Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 2Health News:The True 9/11 Hero Story “Color of Honor” Premieres in Germany and Bangladesh: Luciana Lagana Plays the Mother of the Lead and Co-Produces with Blaise Dolcemaschio. 3
... help decrease the risk of breast cancer in postmenopausal women. ... ages 50 and 79 years old. The women were assessed ... on how many hours per week they exercised. The level ... 50 years was also considered. Researchers documented cases of breast ...
... group of cells, called satellite cells, that line the ... // their youthfulness. These cells rescue damaged muscles and ... new cells for future repairs. Previous studies have shown ... is activated by another protein called Delta. ,Researchers ...
... study reports the vessels in the eyes may be ... appears to narrow before blood // pressure exceeds normal ... to photograph the retinas of more than 3,500 people. ... Researchers also measured the blood pressure of the patients ...
... New research shows heart attacks without chest pain are more ... heart attack. Instead of chest pain //, some patients experience ... and vomiting. ,Researchers conducted a study to see how ... treated and how they recover. The study included information on ...
... new research chemotherapy after surgery may not be better ... cancer patients. // However, researchers say, the study looked ... new chemotherapy regimens may be better. ,In 1977, ... after surgery was initiated. More than 1,000 patients with ...
... Researchers have now found a way to genetically engineer the ... leaving healthy ones intact.// They did this by modifying one ... they had to boost the activity of another gene to ... Specialists say, “When the virus infects cells, it takes the ...
Cached Medicine News:
... the equivalent of 7.5 liters out of your ... need two machines for your high-flow patients! , ... Oxygen-Conserving Devices function like standard conservers, because they ... oxygen required to saturate a patient. However, ...
Proven and Efficient Stand-Alone Device. International Model. 50 psi....
Lightweight Pneumatic Conserver., ,NOTE: All models passed the ASTM PS 127-00 regulator ignition safety test....
... ,Offers an average 5:1 increase in usage time ... of a standard cannula. , ,The combination ... ambulatory oxygen patients a superior alternative to liquid ... warranty. , ,NOTE: ...
Medicine Products: